Table 4 Description of the interface molecular events at the atomic level in the TLRs-hMPV beta1 and MHCs-hMPV beta1 docked complexes.

From: Rational design and in silico characterization of a multiepitope mRNA vaccine candidate against human metapneumovirus (hMPV) using reverse vaccinology and immunoinformatics approaches

Complex description

No. of residues in the interface

No. of Salt bridges

No. of hydrogen bonds

No. of nonbonded contacts

Interface area (Å2)

TLR-4

36

08

16

214

1610

hMPV beta1

30

1717

TLR-2

30

05

17

165

1508

hMPV beta1

27

1567

MHC-I-hMPV beta1-complex

14–19 (A-C)

02 (A-C)

02 (A-C)

95 (A-C)

934–936 (A-C)

1–3 (B-C)

1 (B-C)

1 (B-C)

03 (A-C)

94 − 77 (B-C)

MHC-II-hMPV beta1-complex

7–12 (A-C)

7–12 (A-C)

03 (A-C)

34 (A-C)

472 − 429 (A-C)

26–28 (B-C)

26–28 (B-C)

10 (B-C)

193 (B-C)

1374–1387 (B-C)

  1. A and B represent the chains of the MHCs, and C represents the vaccine construct (hMPV beta1).